eXmoor Pharma and UCL establish strategic cell and gene therapy collaboration

eXmoor Pharma has entered a strategic collaboration with University College London (UCL) and its Translational Research Office (TRO) to accelerate the development of cell and gene therapies (CGT). The partnership is designed to streamline the entire CGT development pathway, from initial academic research through to clinical application.

The collaboration will facilitate engagement between UCL innovators and eXmoor's multidisciplinary teams. It integrates the TRO's translational research expertise with eXmoor's consultancy, development, and Good Manufacturing Practice (GMP) capabilities, aiming to overcome common technical and regulatory delays in CGT development.

As part of the agreement, UCL researchers will gain access to eXmoor's experts and services, including input on grants, regular consultancy clinics, joint events, and GMP manufacturing for early-stage clinical studies. In return, eXmoor will work directly with UCL's researchers, ensuring its teams remain current with the latest CGT modalities and innovations.

UCL officials highlighted the university's strong pipeline of Advanced Therapy Medicinal Products (ATMPs) and commitment to life-changing innovation. eXmoor brings over twenty years of consultancy experience in CGT manufacturing and commercialization. The TRO's role is to translate UCL's biomedical research into practical applications like drugs and diagnostics.

Leadership from both organizations emphasized that this collaborative model, which pairs academic science with practical, GMP-ready solutions, is essential for successfully moving groundbreaking therapies from the laboratory to patients.